Cost-effectiveness analysis: what it really means for transfusion medicine decision making.
about
Cost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States.[Preoperative anemia in orthopedic surgery: clinical impact, diagnostics and treatment].Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomesToward a patient-based paradigm for blood transfusion.The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop.Health economics and outcomes methods in risk-based decision-making for blood safety.Human T-lymphotropic virus and transfusion safety: does one size fit all?An assessment of differences in costs and health benefits of serology and NAT screening of donations for blood transfusion in different Western countries.Transfusion-transmitted babesiosis leading to severe hemolysis in two patients with sickle cell anemia.Babesia microti: From Mice to Ticks to an Increasing Number of Highly Susceptible Humans.Are there ethical differences between stopping and not starting blood safety measures?The Precautionary Principle and the Tolerability of Blood Transfusion Risks.The future of red blood cell alloimmunization risk reduction.The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden.Good evidence begets good policy: or so it should be.Epidemiologic and laboratory findings from 3 years of testing United States blood donors for Trypanosoma cruzi.The outcome of donor screening for human T-cell lymphotropic virus infection in The Netherlands.
P2860
Q33688664-4CC8666C-FFCD-4383-BDFE-97989A7C344AQ34020541-5CCD46DC-DB88-4635-98A8-9386BC425F27Q36058580-75DBCE1B-7859-429A-9530-9530A728CDE2Q37568315-3950B8B6-45A6-4C57-95B0-7D0EE0C7E3A3Q38001037-09C4EDE0-D28C-41E7-A9BA-7656F8DCE1C0Q38412277-1148CF3F-F560-4763-AB46-322A0FCFC945Q38590004-F4E93138-19EA-4492-920D-6881F77F191CQ38714326-80195CCC-96AF-4D63-9D8E-80217E42AFAFQ40110167-2C46BC1E-D2D7-49D3-852B-06C2DEA01F0BQ40118377-6284A3CF-EFD7-48CB-AFBC-C6FFF39B28B6Q40228627-AFA764DD-17B5-4F85-A83F-51D33BAED253Q40330073-E87B855D-640D-4845-83A0-D9C1BDBA8C15Q42549198-6998C773-C502-41BD-8088-4E796A751929Q43000009-E1E4DA68-4A1E-4951-AB51-3E52FA882B21Q44083868-D99DC86B-6897-4C84-BC04-70BB95568374Q44607453-6B56C224-14A8-475C-8B3B-D08F0EA2E7CDQ45363593-3C715299-F0B0-494E-A855-5E8BD1590A4A
P2860
Cost-effectiveness analysis: what it really means for transfusion medicine decision making.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness analysis: w ...... sion medicine decision making.
@en
Cost-effectiveness analysis: w ...... sion medicine decision making.
@nl
type
label
Cost-effectiveness analysis: w ...... sion medicine decision making.
@en
Cost-effectiveness analysis: w ...... sion medicine decision making.
@nl
prefLabel
Cost-effectiveness analysis: w ...... sion medicine decision making.
@en
Cost-effectiveness analysis: w ...... sion medicine decision making.
@nl
P1476
Cost-effectiveness analysis: w ...... sion medicine decision making.
@en
P2093
Brian Custer
P356
10.1016/J.TMRV.2008.09.001
P577
2009-01-01T00:00:00Z